Noctamid (Lormetazepam)

Lormetazepam, the active ingredient in Noctamid, is a benzodiazepine presented as an oral tablet for oral use. It acts as a hypnotic, indicated for short‑term treatment of insomnia in adult patients who have difficulty initiating or maintaining sleep. The medication belongs to the class of central nervous system depressants and is prescribed when non‑pharmacologic measures are insufficient.

GNH USA supplies Noctamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lormetazepam is a benzodiazepine hypnotic used to manage sleep‑related disorders. - Insomnia: short‑term treatment improves sleep onset and maintenance in adults. - Sleep initiation difficulty: reduces the time needed to fall asleep. - Sleep maintenance difficulty: decreases the number of nocturnal awakenings.

Lormetazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent lack of energy. - Impaired coordination: reduced motor control. - Headache: mild to moderate pain in the head.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Dependence or addiction: risk of physical and psychological reliance with prolonged use. - Withdrawal seizures: convulsions upon abrupt discontinuation after extended therapy.

Before prescribing Lormetazepam, clinicians should consider several safety measures. - Assess duration of sleep disorder: limit therapy to short‑term periods to avoid dependence. - Avoid concurrent CNS depressants: increased risk of excessive sedation. - Monitor elderly patients: higher susceptibility to falls and confusion. - Use caution in respiratory disease: potential for worsened breathing. - Store at room temperature: keep in the original pack, protect from moisture.

Lormetazepam can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Other benzodiazepines: additive central nervous system depression. - Opioids: heightened risk of respiratory depression and profound sedation. - Alcohol: synergistic increase in drowsiness and impairment.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants: may increase sedation. - Antihistamines: additive drowsy effect. - CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma concentrations of lormetazepam.